We're On a Mission to Help Reduce the Incidence of Late Stage Cancer Through Early Interventions
Today most cancer research is focused on the “Moonshot” a cure for cancer. But at StageZero Life Sciences we believe in “groundshots” too, by doing whatever we can to help improve outcomes through cancer prevention, earlier cancer detection and adjunctive cancer therapies.
(NEX:SZLS.H) (OTCQB:SZLSF)
Learn More About our ARISTOTLE test by watching the video below.
Follow Us on Social Media!
For questions about investor relations, please fill out the form below.
StageZero listed warrants
Please note that the recent TSX bulletin regarding the Trading Halt of the StageZero Listed warrants TSX Symbol: SZLS.WS, relates solely to the warrants. These warrants have come to term and will no longer be trading.
Early Cancer Detection
StageZero Life Sciences is dedicated to finding cancer in the earliest stages when it is most curable. Our next-generation test, ARISTOTLE®, can simultaneously screen for multiple cancers from a single blood sample. ARISTOTLE has been built on the company’s mRNA Sentinel Principle Technology® Platform, which has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
Cancer Prevention & Adjunctive Cancer Therapies
Investor Presentation
Annual General and Special Meeting
Conference Call
Time: 2:00pm ET
Webcast Link: https://www.gowebcasting.com/12586
Conference Call Numbers
Canada/USA TF: 1-800-319-4610
Toronto Toll: +1-416-915-3239
International Toll: +1-604-638-5340
StageZero Life Sciences Q3 2022 Earnings Call / Presentation
In The News
StageZero Life Sciences was recently featured on BNN Bloomberg